A subacute toxicity study of a potent tetanus toxoid (250 Lf) was carried out in guinea pigs.The toxoid was injected subcutaneously at the nape of the neck at dose levels of 1.0, 1.5.and 2.0 ml in Groups Ⅱ. Ⅲ. and ...A subacute toxicity study of a potent tetanus toxoid (250 Lf) was carried out in guinea pigs.The toxoid was injected subcutaneously at the nape of the neck at dose levels of 1.0, 1.5.and 2.0 ml in Groups Ⅱ. Ⅲ. and Ⅳ, respectively.In the controls (Group Ⅰ) 2.0 ml of aluminum phosphate suspension was given in each injection.Periodic evaluations of body weight, food/water intake, general observable behavior, hematology.and blood chemistry in toxoid-injected guinea pigs were similar to those in control guinea pigs.Thus, the toxoid did not cause any side effects up to four times the dose proposed for humans.1990 Academic Press, Inc.展开更多
Proteus species especially Proteus mirabilis and Proteus vulgaris are zoonotic pathogens which can cause public health disease.Owing to their antibiotic-resistance,developing vaccines against these pathogens is urgent...Proteus species especially Proteus mirabilis and Proteus vulgaris are zoonotic pathogens which can cause public health disease.Owing to their antibiotic-resistance,developing vaccines against these pathogens is urgently required.Herein,we describe the first synthesis of the common O-antigen of Proteus mirabilis OE and Proteus vulgaris TG 103.展开更多
The Ebola virus(EBOV)is a member of the Orthoebolavirus genus,Filoviridae family,which causes severe hemorrhagic diseases in humans and non-human primates(NHPs),with a case fatality rate of up to 90%.The development o...The Ebola virus(EBOV)is a member of the Orthoebolavirus genus,Filoviridae family,which causes severe hemorrhagic diseases in humans and non-human primates(NHPs),with a case fatality rate of up to 90%.The development of countermeasures against EBOV has been hindered by the lack of ideal animal models,as EBOV requires handling in biosafety level(BSL)-4 facilities.Therefore,accessible and convenient animal models are urgently needed to promote prophylactic and therapeutic approaches against EBOV.In this study,a recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein(VSV-EBOV/GP)was constructed and applied as a surrogate virus,establishing a lethal infection in hamsters.Following infection with VSV-EBOV/GP,3-week-old female Syrian hamsters exhibited disease signs such as weight loss,multi-organ failure,severe uveitis,high viral loads,and developed severe systemic diseases similar to those observed in human EBOV patients.All animals succumbed at 2–3 days post-infection(dpi).Histopathological changes indicated that VSV-EBOV/GP targeted liver cells,suggesting that the tissue tropism of VSV-EBOV/GP was comparable to wild-type EBOV(WT EBOV).Notably,the pathogenicity of the VSV-EBOV/GP was found to be species-specific,age-related,gender-associated,and challenge route-dependent.Subsequently,equine anti-EBOV immunoglobulins and a subunit vaccine were validated using this model.Overall,this surrogate model represents a safe,effective,and economical tool for rapid preclinical evaluation of medical countermeasures against EBOV under BSL-2 conditions,which would accelerate technological advances and breakthroughs in confronting Ebola virus disease.展开更多
文摘A subacute toxicity study of a potent tetanus toxoid (250 Lf) was carried out in guinea pigs.The toxoid was injected subcutaneously at the nape of the neck at dose levels of 1.0, 1.5.and 2.0 ml in Groups Ⅱ. Ⅲ. and Ⅳ, respectively.In the controls (Group Ⅰ) 2.0 ml of aluminum phosphate suspension was given in each injection.Periodic evaluations of body weight, food/water intake, general observable behavior, hematology.and blood chemistry in toxoid-injected guinea pigs were similar to those in control guinea pigs.Thus, the toxoid did not cause any side effects up to four times the dose proposed for humans.1990 Academic Press, Inc.
基金This work was financially supported by the National Natural Science Foundation of China(22167015,22077052,22177041,21977039)Science and Technology Department of Jiangxi Province(jxsq2020101084).
文摘Proteus species especially Proteus mirabilis and Proteus vulgaris are zoonotic pathogens which can cause public health disease.Owing to their antibiotic-resistance,developing vaccines against these pathogens is urgently required.Herein,we describe the first synthesis of the common O-antigen of Proteus mirabilis OE and Proteus vulgaris TG 103.
基金supported by National Key R&D Program of China(grant number 2023YFC2605500)Jilin Province Youth Talent Support Project(grant number QT202208)+1 种基金the Ministry of Science and Technology of the People's Republic of China(grant number 2022YFC0867900)Nation Key Research and Development Program of China,New technology of rapid of pathogens in laboratory animals(grant number 2021YFF07033600).
文摘The Ebola virus(EBOV)is a member of the Orthoebolavirus genus,Filoviridae family,which causes severe hemorrhagic diseases in humans and non-human primates(NHPs),with a case fatality rate of up to 90%.The development of countermeasures against EBOV has been hindered by the lack of ideal animal models,as EBOV requires handling in biosafety level(BSL)-4 facilities.Therefore,accessible and convenient animal models are urgently needed to promote prophylactic and therapeutic approaches against EBOV.In this study,a recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein(VSV-EBOV/GP)was constructed and applied as a surrogate virus,establishing a lethal infection in hamsters.Following infection with VSV-EBOV/GP,3-week-old female Syrian hamsters exhibited disease signs such as weight loss,multi-organ failure,severe uveitis,high viral loads,and developed severe systemic diseases similar to those observed in human EBOV patients.All animals succumbed at 2–3 days post-infection(dpi).Histopathological changes indicated that VSV-EBOV/GP targeted liver cells,suggesting that the tissue tropism of VSV-EBOV/GP was comparable to wild-type EBOV(WT EBOV).Notably,the pathogenicity of the VSV-EBOV/GP was found to be species-specific,age-related,gender-associated,and challenge route-dependent.Subsequently,equine anti-EBOV immunoglobulins and a subunit vaccine were validated using this model.Overall,this surrogate model represents a safe,effective,and economical tool for rapid preclinical evaluation of medical countermeasures against EBOV under BSL-2 conditions,which would accelerate technological advances and breakthroughs in confronting Ebola virus disease.
